Recap: Prime Medicine Q4 Earnings
Portfolio Pulse from Benzinga Insights
Prime Medicine (NASDAQ:PRME) reported Q4 earnings with an EPS of $-0.72, missing estimates by -41.0%. Revenue remained unchanged from the previous year. Despite missing EPS estimates last quarter, PRME's share price increased by 18.0% the following day.

March 01, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Prime Medicine reported a significant miss in Q4 earnings with an EPS of $-0.72, underperforming estimates by -41.0%. Revenue remained steady compared to last year.
The significant miss in earnings estimates for PRME is likely to have a negative short-term impact on its stock price, considering the magnitude of the miss (-41.0%). However, it's important to note that despite a miss in EPS estimates in the previous quarter, the stock price increased by 18.0% the following day, indicating that market reactions can be unpredictable. The unchanged revenue year-over-year also adds to the uncertainty regarding the stock's short-term movement.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100